Search Results for: treatment

By Kuldip K. Ambastha The stock of BeiGene, Ltd. (BGNE), a commercial stage biopharmaceutical company focused on cancer treatment drugs, saw a +20.5% increase in price per share on Wednesday, October 12, 2022. Brukinsa (zanubrutinib) in its Phase 3 trial data showed highly positive results in people with chronic lymphocytic leukemia (CLL) or small lymphocytic …

Continue reading “What Caught Our Attention in the Investment World? – Week of October 10-14, 2022”

By Kuldip K. Ambastha On Friday, September 3, 2021, the stock of Forte Biosciences, Inc. (FBRX) stood out for its substantial trading day loss of -82.3%. Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on potential treatments for inflammatory skin diseases. The company released results of a Phase 2 clinical trial of FB-401, related …

Continue reading “What Caught Our Attention in the Investment World? – Week of August 30-September 3, 2021”

By Kuldip K. Ambastha Biogen Inc. (BIIB), a biotech company, had a memorable Monday of this past trading week. On Monday, June 7, 2021, Biogen had a +38.3% gain for the day on its stock. Biogen’s Alzheimer’s disease treatment was approved by the U.S. Food and Drug Administration (FDA) as part of an accelerated approval …

Continue reading “What Caught Our Attention in the Investment World? – Week of June 7-11, 2021”

By Kuldip K. Ambastha Biogen Inc. (BIIB) had a -7.5% return on Thursday, June 18, 2020. On this day, Biogen Inc. lost a legal dispute (over a patent) being heard by a U.S. district court. The patent dispute centered on a multiple sclerosis treatment drug called Tecfidera, which uses dimethyl fumarate as its main active …

Continue reading “What Caught Our Attention in the Investment World? – Week of June 15 – 19, 2020”

By Kuldip K. Ambastha and Anil K. Ambastha On Monday, December 9, 2019, big news emerged in the mergers & acquisitions field in terms of Merck & Co., Inc. (MRK) buying ArQule, Inc. (ARQL) and Sanofi SA (SNY) buying Synthorx Inc. (THOR). Both Merck and Sanofi bought the smaller companies to enhance their capabilities in …

Continue reading “What Caught Our Attention in the Investment World? – Week of December 9-13, 2019”

By Kuldip K. Ambastha and Anil K. Ambastha On Thursday, December 5, 2019, there was “a tale of two cities,” to quote Charles Dickens. In the biotech arena, SAGE (Sage Therapeutics, Inc.) and AUPH (Aurinia Pharmaceuticals Inc.) were big movers. Sage Therapeutics delivered -59.7% for the day, while Aurinia Pharmaceuticals returned 78.8%. SAGE-217 is a …

Continue reading “What Caught Our Attention in the Investment World? – Week of December 2-6, 2019”

By Kuldip K. Ambastha and Anil K. Ambastha Karuna Therapeutics Inc. (KRTX), a clinical-stage biopharmaceutical company, was founded in 2009 and is headquartered in Boston, MA. The company is focused on developing innovative therapies for individuals suffering from disabilities, disorders, and pain. Karuna Therapeutics Inc. has announced that its schizophrenia treatment’s Phase 2 clinical trial …

Continue reading “What Caught Our Attention in the Investment World? – Week of November 18-22, 2019”

By Kuldip K. Ambastha and Anil K. Ambastha On October 22, 2019, Biogen Inc. (BIIB) delivered a 26.1% return for the day. This was the stock’s largest one-day percentage return in 23 years. Its Alzheimer’s drug (aducanumab) had previously been written off as a failure, but now will be getting a second chance at approval …

Continue reading “What Caught Our Attention in the Investment World? – Week of October 21-25, 2019”